Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company operates within the biopharmaceutical and oncology industries, with a primary emphasis on hematologic malignancies and genetically defined cancers. Syndax’s strategy centers on targeting cancer biology through epigenetic modulation and precision oncology approaches.
The company’s principal revenue driver is REVTYRA® (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A rearrangement. In addition to its commercial product, Syndax maintains a development pipeline aimed at addressing high-unmet-need cancer indications. Founded in 2005, the company initially focused on endocrine therapies before pivoting to oncology, later advancing epigenetic programs that reshaped its long-term strategy and led to its transition into a commercial-stage enterprise.
Business Operations
Syndax conducts its operations primarily through a single reportable segment focused on the research, development, and commercialization of oncology therapeutics. Revenue generation is currently driven by U.S. sales of REVTYRA®, while additional pipeline candidates remain in clinical development. Research and development activities include clinical trials, regulatory engagement, and manufacturing coordination, with most laboratory and production functions outsourced to third-party partners.
Operations are predominantly U.S.-based, though clinical trials and regulatory planning involve international sites. Syndax does not own large-scale manufacturing facilities and instead relies on contract manufacturing organizations and clinical research organizations. The company maintains full commercial responsibility for its approved product and retains global development and commercialization rights for its pipeline assets.
Strategic Position & Investments
Syndax’s strategic direction focuses on expanding the commercial potential of REVTYRA® into additional indications and advancing its pipeline of targeted oncology agents. A key growth initiative includes the clinical development of axatilimab, a monoclonal antibody targeting CSF-1R, being developed for chronic graft-versus-host disease and other immune-mediated conditions, in collaboration with Incyte Corporation.
The company has invested heavily in late-stage clinical development and regulatory capabilities to support lifecycle expansion. Syndax does not operate as a diversified holding company but maintains a concentrated portfolio centered on precision oncology and immune-modulating therapies. Its competitive positioning is defined by first-in-class or best-in-class aspirations within narrowly defined genetic or immunologic patient populations.
Geographic Footprint
Syndax Pharmaceuticals is headquartered in Waltham, Massachusetts, United States, which serves as the central hub for corporate leadership, clinical development, and commercial operations. The company’s commercial activities are currently focused on the United States, where its approved product is marketed.
Internationally, Syndax has a limited direct operational presence but participates in Europe, Asia-Pacific, and other regions through global clinical trials and regulatory planning. Future geographic expansion is expected to occur primarily through regulatory approvals, partnerships, or distributors rather than the establishment of large physical international offices.
Leadership & Governance
Syndax is led by an experienced executive team with backgrounds in oncology drug development, commercialization, and corporate governance. The leadership emphasizes disciplined clinical execution, regulatory rigor, and focused capital allocation to maximize the value of its oncology portfolio.
Key executives include:
- Michael A. Metzger – Chief Executive Officer
- Mark Velleca, M.D., Ph.D. – Chief Scientific Officer
- Chris Koenig – Chief Financial Officer
- Michael McBride – Chief Operating Officer
- Brigette Heller – Chief Legal Officer and Secretary
The board of directors provides oversight with a focus on long-term value creation, regulatory compliance, and alignment with shareholder interests, consistent with governance standards applicable to U.S. publicly traded biopharmaceutical companies.